Table 2.
Patient details of panel positive in ESCC patients
| P53 | NY‐ESO‐1 | |||||
|---|---|---|---|---|---|---|
| Positive | − | + | − | + | ||
| Number | 57 (67.1%) | 28 (32.9) | 60 (90.3%) | 25 (9.7) | ||
| Gender | ||||||
| Male (%) | 49 (57.6) | 24 (28.2) | P = .764 | 54 (63.4) | 19 (22.4) | P = .178 |
| Female | 8 (9.4) | 4 (4.7) | 6 (7.1) | 6 (7.1) | ||
| Mean age ± s.d. (y) | 68.8 ± 7.8 | 67.0 ± 7.2 | 67.7 ± 7.5 | 69.4 ± 8.0 | ||
| Age range (y) | 45‐85 | 58‐82 | 45‐85 | 60‐84 | ||
| T‐classification | ||||||
| T1 | 19 (22.4) | 9 (10.6) | P = .912 | 25 (29.4) | 3 (3.5) | P < .005 |
| T2 | 6 (7.1) | 2 (2.4) | 7 (8.2) | 1 (1.2) | ||
| T3 | 18 (21.2) | 11 (12.9) | 12 (14.1) | 17 (20.0) | ||
| T4 | 18 (21.2) | 6 (7.1) | 16 (18.8) | 4 (4.7) | ||
| Lymph node metastasis | ||||||
| Positive | 37 (43.5) | 19 (22.4) | P = .979 | 35 (41.2) | 21 (24.7) | P = .023 |
| Negative | 20 (23.5) | 9 (10.6) | 25 (29.4) | 4 (4.7) | ||
| Distant metastasis | ||||||
| Positive | 11 (12.9) | 8 (9.4) | P = .412 | 10 (11.8) | 9 (10.6) | P = .096 |
| Negative | 46 (54.1) | 20 (23.5) | 50 (58.8) | 16 (18.8) | ||
| TNM stage | ||||||
| I | 19 (22.4) | 7 (8.2) | P = .325 | 24 (28.2) | 2 (2.4) | P = .063 |
| II | 2 (2.4) | 5 (5.9) | 4 (4.7) | 3 (3.5) | ||
| III | 14 (16.5) | 5 (5.9) | 10 (11.8) | 9 (10.6) | ||
| IV | 22 (25.9) | 11 (12.9) | 22 (25.9) | 11 (12.9) | ||
| CEA | ||||||
| Positive | 13 (15.3) | 8 (9.4) | P = .755 | 15 (17.6) | 6 (7.1) | P = .858 |
| Negative | 44 (51.8) | 20 (23.5) | 45 (52.9) | 19 (22.4) | ||
| SCC | ||||||
| Positive | 23 (27.1) | 12 (14.1) | P = .825 | 22 (22.4) | 13 (15.3) | P = .191 |
| Negative | 34 (40.0) | 16 (18.8) | 38 (67.1) | 12 (14.1) | ||
Abbreviations: CEA, carcinoembryonic antigen; s.d., standard deviation.
Factors with statistically significant differences are indicated by bold P‐values.